Table 2 Factors associated with initiation of LTBI therapy more than 5 years after arrival to the U.S.
Length of U.S. Residence | ||
|---|---|---|
1 – 5 years | > 5 years | |
AOR* (95% CI) | AOR* (95% CI) | |
Gender | ||
Male | Reference | |
Female | 1.3 (1.0–1.8) | 1.8 (1.2–2.6) |
Age | ||
< 35 | Reference | |
≥ 35 | 1.9 (1.2–3.0) | 4.1 (2.5–6.6) |
Region of Origin | ||
Africa | Reference | Reference |
Latin America & Caribbean | 0.7 (0.5–1.0) | 1.9 (1.3–3.0) |
Asia | 0.6 (0.3–1.0) | 1.7 (0.9–3.2) |
Canada & Europe | 0.6 (0.1–2.4) | 1.4 (0.2–7.5) |
HIV Status | ||
Negative | Reference | |
Positive | 1.2 (0.2–5.7) | 0.6 (0.1–3.5) |
Unknown | 2.4 (1.5–4.0) | 1.1 (0.6–1.9) |
Referral | ||
Immigration | Reference | Reference |
Primary Medical Doctor | 38.3 (19.6–74.6) | 251.7 (78.4–808.2) |
Other** | 24.8 (14.9–41.2) | 113.7 (38.5–335.6) |